Morgan Stanley Downgrades Atea Pharmaceuticals (AVIR) to Underweight
Tweet
Share
E-mailGet Alerts AVIR Hot Sheet
Price: $5.38 +6.32%
Rating Summary:
2 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 15 | New: 9
Rating Summary:
2 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 15 | New: 9
Join SI Premium – FREE
Morgan Stanley analyst Matthew Harrison downgraded Atea Pharmaceuticals (NASDAQ: AVIR) from Equalweight to Underweight with a price target of $7.00.
For an analyst ratings summary and ratings history on Atea Pharmaceuticals click here. For more ratings news on Atea Pharmaceuticals click here.
Shares of Atea Pharmaceuticals closed at $8.30 yesterday.
You May Also Be Interested In
- Atea Pharmaceuticals (AVIR) PT Raised to $7 at Morgan Stanley
- Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
- Freedom Broker Double Downgrades Mosaic (MOS) to Sell
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
